Key facts
- It has raised $100.0M across 6 recorded rounds; the latest was PIPE ($100.0M) in Mar 2025.
- 1 institutional filer reports fund marks on Aclaris Therapeutics across 2 filings.
- Aclaris Therapeutics has filed 8 Form Ds with the SEC since 2012, most recently Dec 2024 ($80.0M sold to 19 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 6 rounds
- ·Watchlist + deal alerts for Aclaris Therapeutics
Create free account
No card required
Funding rounds
6 roundsMar 2025PIPE$100.0M▮
Apr 2022PIPE—▮
About Aclaris Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Aclaris Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Aclaris Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest May 20251 SEC-registered fund reported 2 fair-value marks on Aclaris Therapeutics between May 2025 and May 2025. Filer-level marks and implied $/share are available to Pro members.